This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.
Research
Latest papers
SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.
Nature communications · 2026 · senior author
ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.
Cancer research communications · 2026
SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.
NPJ precision oncology · 2026 · senior author
Latest funding
- $1,338,908
Investigating and targeting pathogenic variants in DICER1-related tumour predisposition
CIHR · 2026 · Principal investigator
- $100,000
Investigating and targeting pathogenic variants in DICER1 tumour predisposition syndrome
CIHR · 2024 · Principal investigator
- $1,116,900
p300 histone acetyltransferase-dependency in SWI/SNF-deficient cancers: mechanisms and therapeutic implications
CIHR · 2024 · Nominated PI
42 publications.
SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.
Aceto G, Liu K, Arabzadeh A, Tsai S, Xue Y, Monast A, Pilon V, Han M, Morin G, Pavlakis K, Fu L, Park M, Foulkes WD, Wang Y, Huang S
ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.
Guay J, Kuasne H, Chabot C, Bozek K, Majedi Y, Buchanan M, Aguilar-Mahecha A, Bareke E, Ulmer B, Kong T, Yang K, Liao M, Elebute O, Guo R, Monast A, Morin G, Huang S, Park M, Basik M
SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.
Jiang J, Zhu X, Fu Z, Liao M, Arabzadeh A, Robert F, Monast A, Pilon V, Pavlakis K, Park M, Foulkes WD, Huang S
Synthesis of long and functionally active RNAs facilitated by acetal levulinic ester chemistry.
Lyu Z, Katolik A, Yaseen I, Pater AA, Robert F, Huang S, Gagnon KT, Unrau PJ, Damha MJ
MAPL regulates gasdermin-mediated release of mtDNA from lysosomes to drive pyroptotic cell death.
Nguyen M, Collier JJ, Ignatenko O, Morin G, Goyon V, Janer A, Tiefensee Ribeiro C, Milnerwood AJ, Huang S, Desjardins M, McBride HM
SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer.
Zhu X, Fu Z, Aceto G, St-Germain J, Liu K, Arabzadeh A, Qi Y, Xue Y, Witkowski L, Graulich E, Steinberger J, Misirlioglu S, Bassani N, Sansal R, Yasmeen A, Morin G, Guo J, Monast A, Pilon V, Valachová A, Pavlakis K, Fu L, Gotlieb WH, McCluggage WG, Huntsman D, Bishop AJR, Levine DA, Park M, Wang Y, Raught B, Foulkes WD, Huang S
TSC2 loss in neural progenitor cells suppresses mRNA translation of neurodevelopmental genes.
Martin P, Szkop KJ, Robert F, Bhattacharyya S, Beauchamp RL, Brenner J, Redmond NE, Huang S, Erdin S, Larsson O, Ramesh V
Discovery of RNA-Protein Molecular Clamps Using Proteome-Wide Stability Assays.
Goldstein SI, Fan AC, Wang Z, Naineni SK, Cencic R, Garcia-Gutierrez SB, Patel K, Huang S, Brown LE, Emili A, Porco JA
Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells.
Meehan B, Adnani L, Zhu X, Tawil N, Garnier D, Nakano I, Huang S, Rak J
Discovery of RNA-Protein Molecular Clamps Using Proteome-Wide Stability Assays.
Goldstein SI, Fan AC, Wang Z, Naineni SK, Cencic R, Garcia-Gutierrez SB, Patel K, Huang S, Brown LE, Emili A, Porco JA
Investigating and targeting pathogenic variants in DICER1-related tumour predisposition
Principal investigators: Foulkes, William D; Fabian, Marc R; Huang, Sidong
Keywords: Cancer Predisposition Syndrome; Dicer1-Related Tumour Predisposition; Microrna Processing; Sarcoma
Investigating and targeting pathogenic variants in DICER1 tumour predisposition syndrome
Principal investigators: Foulkes, William D; Fabian, Marc R; Huang, Sidong
Keywords: Cancer Predisposition Syndrome; Dicer1 Tumour Predisposition Syndrome; Microrna Processing; Sarcoma
p300 histone acetyltransferase-dependency in SWI/SNF-deficient cancers: mechanisms and therapeutic implications
Principal investigators: Huang, Sidong
Keywords: Histone Acetyltransferase; P300; Smarca4; Swi/Snf
Exploiting Dysregulated mRNA Translation to Unveil Novel Therapeutic Vulnerabilities in Metastatic Breast Cancers
Principal investigators: Huang, Sidong; Ursini-Siegel, Giuseppina
Keywords: Breast Cancer; Combination Therapy; Eif4a; Helicase Inhibitor; Metastasis; Mrna Translation
Leveraging Epigenetic Reprogramming for Targeted Therapy in ARID1A/ARID1B Dual-Deficient Cancers
Principal investigators: Wang, Yemin
Keywords: Arid1a; Arid1b; Chromatin-Remodelling; Dedifferentiated Endometrial Cancer; Epigenetic Reprogramming; Swi/Snf
Dissecting and targeting SWI/SNF loss in de-differentiated endometrial carcinomas
Principal investigators: Postovit, Lynne-Marie
Keywords: Chromatin; Clonal Evolution; Dedifferentiation; Swi/Snf; Synthetic Lethality
Exploiting genetic vulnerabilities to improve outcomes in small cell carcinoma of the ovary
Principal investigators: Huang, Sidong
Keywords: Drug Resistance; Functional Genetics; Parp Inhibitors; Small Cell Ovarian Carcinoma; Smarca4; Synthetic Lethal Screen; Targeted Cancer Therapy; Variants Of Uncertain Significance
Canada Research Chair Tier 2
Principal investigators: Huang, Sidong
Keywords: Crc
Uncovering tumour-intrinsic effectors and regulators of PD-L1 in triple-negative breast cancer.
Principal investigators: Huang, Sidong
Keywords: Tumour-Intrinsic Effectors
Targeting vulnerabilities in SMARCA4-deficient lung cancers
Principal investigators: Huang, Sidong
Keywords: Cdk4/6 Inhibitors; Drug Resistance; Functional Genetics; Lung Cancer; Swi/Snf; Synthetic Lethal Screen; Targeted Cancer Therapy
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Biochemistry
- Oncology
- Molecular Oncology
- Pediatrics
- Human Genetics
- Biomedical Engineering
- Department of Molecular Genetics
- Other
Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Morag Park
Oncology
17 shared papers, latest 2026
Morag Park
Oncology
16 shared papers, latest 2026
Jerry Pelletier
Biochemistry
9 shared papers, latest 2024
Janusz Rak
Pediatrics
7 shared papers, latest 2025
Yasser Riazalhosseini
Human Genetics
4 shared papers, latest 2024
Yemin Wang
Faculty
3 shared papers, latest 2026
Mark Lathrop
Faculty
3 shared papers, latest 2018
Michael Witcher
Oncology
3 shared papers, latest 2020
ATILLA Omeroglu
Biomedical Engineering
2 shared papers, latest 2024
William Lockwood
Faculty
2 shared papers, latest 2023
Ivan Topisirovic
Lady Davis Institute for Medical Research
2 shared papers, latest 2024
Lynne-Marie Postovit
Oncology
2 shared papers, latest 2023
Shawn McGuirk
Faculty
2 shared papers, latest 2022
Mark Basik
Social Studies of Medicine
2 shared papers, latest 2026
Julie St-Pierre
Biochemistry, Microbiology and Immunology
2 shared papers, latest 2022
Lynne-Marie Postovit
Biomedical and Molecular Sciences
2 shared papers, latest 2023
Jonathan Spicer
Faculty
2 shared papers, latest 2023
Anne-Claude Gingras
Department of Molecular Genetics
2 shared papers, latest 2024
David Huntsman
Molecular Oncology
2 shared papers, latest 2025
Julie St-Pierre
Faculty
1 shared papers, latest 2021
David Dankort
Biology
1 shared papers, latest 2024
Brian Raught
Research Institute
1 shared papers, latest 2025
Arnim Pause
Biochemistry
1 shared papers, latest 2022
Anastasia Nijnik
Physiology
1 shared papers, latest 2021
Nada Jabado
Pediatrics
1 shared papers, latest 2024
Quaid Morris
Donnelly Centre
1 shared papers, latest 2024
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.